GlassScriptPhysician profile
Steven C Coxe
NPI 1962635300
$1,389.92
in general payments reported to CMS, 2019-2025
27 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2023: $233 · 2024: $280 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.10 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $185.10 | 2023-2025 | Tezspire, Breztri, Fasenra |
| Harmony Biosciences LLC | $170.07 | 2023-2025 | Wakix |
| Viatris Specialty LLC | $74.07 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $68.61 | 2024-2025 | Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $51.19 | 2021 | |
| Glaxosmithkline, LLC. | $47.50 | 2024-2025 | Nucala |
| Jazz Pharmaceuticals INC. | $46.12 | 2025 | |
| Philips North America LLC | $45.20 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $44.99 | 2023-2025 | Dupixent |
| Verona Pharma, INC. | $38.78 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.83 | 2025 | Ofev |
| Pulmonx Corporation | $36.81 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Inspire Medical Systems, INC. | $36.81 | 2023 | Inspire |
| Actelion Pharmaceuticals US, INC. | $31.80 | 2025 | Uptravi, Opsynvi, Opsumit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $31.70 | 2025 | Smartvest |
| Itamar Medical INC | $23.57 | 2023 | Watchpatone |
| Axsome Therapeutics, INC. | $22.74 | 2023 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $22.62 | 2025 | Lumryz |
| Lilly USA, LLC | $21.13 | 2025 | Zepbound |
| Genzyme Corporation | $20.18 | 2023 | |
| Nestle Healthcare Nutrition INC. | $18.96 | 2021 | |
| Celgene Corporation | $18.05 | 2021 | |
| Astellas Pharma US INC | $17.83 | 2024 | Cresemba |
| Mylan Specialty L.P. | $16.33 | 2024 | Yupelri |
| Baxter Healthcare | $16.30 | 2023 | Hillrom - Life 2000 Ventilation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Coxe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.